FDA panel rejects Novartis' heart failure hope serelaxin
An FDA advisory committee voted unanimously against approval of Novartis' acute heart failure (AHF) candidate serelaxin yesterday, although the company says it will stick with the project. As predicted, the panel agreed with the position taken by the ...
FDA Panel Rejects Novartis Drug for Heart Failure
FDA panel votes against Novartis drug for acute heart failure
UPDATE 2-FDA panel votes against Novartis drug for acute heart failure